Trial Profile
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2020
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms PILLAR
- Sponsors Astellas Pharma
- 28 Jul 2020 Results published in the Drugs and Aging
- 31 Aug 2018 Results (n=888) presented at the 48th Annual Meeting of the International Continence Society.
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.